Drug interaction study for IPF patients taking multiple medications

NCT ID NCT06241560

Recruiting now Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how pirfenidone changes the amount of a new medicine (BI 1015550) in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month. Researchers will measure blood levels to understand how the medicines interact, helping guide safe use together.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

LTD "Aversi clinic"
RECRUITING

Tbilisi, 160, Georgia

Contact Phone: •••-•••-•••• Email: •••••@•••••
LTD The First Medical Center
RECRUITING

Tbilisi, 0180, Georgia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Renovatio Clinical-The Woodlands-69551
RECRUITING

The Woodlands, Texas, 77380, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••